AR097732A1 - Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación - Google Patents

Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Info

Publication number
AR097732A1
AR097732A1 ARP140103512A ARP140103512A AR097732A1 AR 097732 A1 AR097732 A1 AR 097732A1 AR P140103512 A ARP140103512 A AR P140103512A AR P140103512 A ARP140103512 A AR P140103512A AR 097732 A1 AR097732 A1 AR 097732A1
Authority
AR
Argentina
Prior art keywords
compositions
factor
heterogenic
populations
coagulation
Prior art date
Application number
ARP140103512A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097732A1 publication Critical patent/AR097732A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
ARP140103512A 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación AR097732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
AR097732A1 true AR097732A1 (es) 2016-04-13

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103512A AR097732A1 (es) 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Country Status (19)

Country Link
US (3) US9757434B2 (enExample)
EP (1) EP3049434A1 (enExample)
JP (1) JP6429885B2 (enExample)
KR (1) KR101988705B1 (enExample)
CN (2) CN105579468A (enExample)
AR (1) AR097732A1 (enExample)
AU (1) AU2014326257B2 (enExample)
BR (1) BR112016005899A8 (enExample)
CA (1) CA2924981C (enExample)
HK (1) HK1218760A1 (enExample)
IL (2) IL244258A0 (enExample)
MX (1) MX373466B (enExample)
MY (1) MY173548A (enExample)
PE (1) PE20160877A1 (enExample)
RU (1) RU2648144C2 (enExample)
SA (1) SA516370751B1 (enExample)
SG (1) SG11201601221XA (enExample)
TW (1) TWI631134B (enExample)
WO (1) WO2015044836A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104994868A (zh) 2013-01-31 2015-10-21 辉瑞公司 用于抵消因子Xa抑制的组合物和方法
PE20160877A1 (es) 2013-09-24 2016-09-11 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
CN110167575B (zh) 2016-06-17 2024-03-15 阿雷克森制药公司 因子xa衍生物的制备
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
PL2915564T3 (pl) * 2007-09-28 2021-07-19 Alexion Pharmaceuticals, Inc. Antidota dla inhibitorów czynnika Xa i sposoby ich stosowania
RU2698392C2 (ru) 2008-06-24 2019-08-26 Октафарма Аг Способ очистки фактора свертывания крови viii
WO2010056765A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ, インコーポレイテッド 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法
DK2591099T3 (da) * 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
BR112015001628A2 (pt) 2012-07-25 2017-11-07 Catalyst Biosciences Inc polipeptídeos de fator x modificados e uso dos mesmos
CN104994868A (zh) 2013-01-31 2015-10-21 辉瑞公司 用于抵消因子Xa抑制的组合物和方法
PE20160877A1 (es) 2013-09-24 2016-09-11 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
WO2015066606A2 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
EP3096779B1 (en) 2014-01-24 2019-12-18 Pfizer Inc Compositions and methods for treating intracerebral hemorrhage

Also Published As

Publication number Publication date
US20210106658A1 (en) 2021-04-15
KR101988705B1 (ko) 2019-06-12
MX2016003871A (es) 2016-08-04
MX373466B (es) 2020-05-25
CA2924981C (en) 2020-03-31
RU2648144C2 (ru) 2018-03-22
TW201524996A (zh) 2015-07-01
CN112195169A (zh) 2021-01-08
EP3049434A1 (en) 2016-08-03
IL279396A (en) 2021-01-31
IL244258A0 (en) 2016-04-21
MY173548A (en) 2020-02-04
US20170333535A1 (en) 2017-11-23
TWI631134B (zh) 2018-08-01
US10660946B2 (en) 2020-05-26
US9757434B2 (en) 2017-09-12
KR20160044034A (ko) 2016-04-22
RU2016108608A (ru) 2017-10-26
SG11201601221XA (en) 2016-04-28
AU2014326257A1 (en) 2016-03-10
CN105579468A (zh) 2016-05-11
CA2924981A1 (en) 2015-04-02
PE20160877A1 (es) 2016-09-11
JP6429885B2 (ja) 2018-11-28
JP2016535071A (ja) 2016-11-10
AU2014326257B2 (en) 2017-08-10
BR112016005899A8 (pt) 2018-02-06
SA516370751B1 (ar) 2018-04-05
BR112016005899A2 (pt) 2017-09-26
WO2015044836A1 (en) 2015-04-02
HK1218760A1 (zh) 2017-03-10
US20150182604A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
MX2018006745A (es) Metodos de tratamiento de neoplasias malignas.
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
IL257986B (en) Expression of recombinant proteins in trichoplusia ni pupae
MX2015003701A (es) Composiciones para tratamiento.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
AR097732A1 (es) Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
EP3634460A4 (en) S-NITROSOGLUTATHIOMA (GSNO) AND REDUCTASE INHIBITORS FOR USE IN THERAPY
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
HUE054330T2 (hu) Graft versus host betegség kezelése transzplantációs betegekben
MX380585B (es) Polipeptidos del factor vii de acción corta.
MX2015014265A (es) Combinacion sinergica de alanina-glutamina, acido hialuronico y un extracto de avena y su uso en una composicion destinada para la curacion de heridas y reparacion de lesiones de la piel.
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
HRP20181352T1 (hr) Postupci i reagensi za održavanje vijabilnosti stanica raka u kirurški odstranjenom tkivu
EP3542808C0 (en) THERAPEUTIC VIRAL MICROPARTICLES TO PROMOTE STENT BIOFUNCTIONALITY AND HEALING IN VERTEBRATE INDIVIDUALS
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
PH12014501044A1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
PH12016500509B1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Legal Events

Date Code Title Description
FB Suspension of granting procedure